However, treatment response between CU subtypes did not significantly differ. Perhaps patients with CindU more often dislike to discontinue treatment due to long disease duration or more often relapse while attempting discontinuation. Also the existence of differences in pathomechanism between CU subtypes may play a role, as the pathophysiology of CU is not completely understood.A limitation of this study might be that drug survival can be influenced by physician and/or patient behaviour regarding prescription and stopping of omalizumab, 10 which is partly intercepted by protocols. Generalization of our results may be limited due to differences in local/national treatment protocols between hospitals/countries. Further multicentre studies from different countries are needed to provide insight into potential differences.In conclusion, in this daily practice study of 142 CU patients, with an observation period up to 6 years, overall drug survival rates for omalizumab were 77%, 61% and 55% after 1, 2 and 3 years, respectively, and mostly determined by well-controlled disease activity. CindU was an independent determinant for overall longer drug survival and decreased risk to discontinue omalizumab due to wellcontrolled disease activity.
CONF LICTS OF INTERESTNone declared.
O R C I D
L. S. Spekhorsthttps://orcid.org/0000-0002-7537-765X
H. RöckmannT A B L E 1 Characteristics of the patients with positive and negative diagnostic skin test results with proton pump inhibitors (PPIs) Patients with positive diagnostic skin test results Patients with negative diagnostic skin test results P value n 62 (75.6%) 20 (24.4%) -Gender (F/M) 53 (85.5%)/9 (14.5%) 18 (90.0%)/2 (10.0%) 0.606 Age, median (min-max) 46 (22-78) 42.5 (22-75) 0.749Time to onset of the reaction after last exposure, median (min-max) hours 1.0 (0.1-8.0) 0.5 (0.1-4.0) 0.823Interval between the reaction and the diagnostic tests, median (min-max) months 3 (0.5-36) 12 (1-60) 0.047
Background
In this study, we aimed to evaluate the sleep quality among chronic urticaria patients using the Chronic Urticaria Quality‐of‐Life Questionnaire (CU–Q2oL), sleep quality assessment tools, and polysomnography and to investigate any relationships between the obtained results.
Methods
The study included 21 patients diagnosed with chronic spontaneous urticaria and 19 healthy controls. We recorded the patients' sleep quality data, including CU–Q2oL, Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), and polysomnography results.
Result
Patients in the chronic urticaria group were more likely to have an ESS score of ≥10 (52.4% vs. 5.3%, p = 0.004) and an apnea‐hypopnea index of ≥5 (44.4% vs. 5.3%, p = 0.017) compared to the control group. In the patient group, the CU–Q2oL total score was positively correlated with sleep latency (r = 0.713, p = 0.004) and PSQI–C1 score (r = 0.726, p = 0.005), while it was negatively correlated with urticaria duration (r = −0.579, p = 0.015), apnea‐hypopnea index (r = −0.607, p = 0.021), longest apnea duration (r = −0.583, p = 0.029), total number of respiratory events (r = −0.618, p = 0.018), and apnea count (r = −0.686, p = 0.007).
Conclusion
We conclude that sleep‐related problems exist among a considerably large proportion of patients with chronic spontaneous urticaria.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.